UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 26, 2012

 

 

MELA Sciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51481   13-3986004

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

50 Buckhout Street, Suite 1

Irvington, New York

  10533
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (914) 591-3783

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 — Submission of Matters to a Vote of Security Holders

The 2012 Annual Meeting of Stockholders (the “Annual Meeting”) of MELA Sciences, Inc. (the “Company”) was held on April 26, 2012.

The Company’s stockholders voted on two proposals as follows: to elect Company directors for the ensuing year (“Proposal 1”); and to ratify the selection by the Audit Committee of the Company’s Board of Directors of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2012 (“Proposal 2”).

All nominees for election to the Board of Directors were elected to serve until the 2013 Annual Meeting of Stockholders and until their respective successors are elected and qualified, or until such director’s earlier death, resignation or removal. The stockholders ratified Proposal 2. The number of votes cast for, against or withheld and the number of abstentions and broker non-votes with respect to each Proposal is set forth below.

 

Proposal 1    Shares For      Shares Withheld      Broker Non-Votes  

Joseph V. Gulfo, MD

     8,603,902         468,311         16,676,567   

Robert Coradini

     8,596,947         475,266         16,676,567   

Anne Egger

     8,552,372         519,841         16,676,567   

Mark Fabiani

     8,569,798         502,415         16,676,567   

John Goddard

     8,582,997         489,216         16,676,567   

Mindy Meads

     8,549,537         522,676         16,676,567   

David K. Stone

     8,384,512         687,701         16,676,567   

LuAnn Via

     8,373,159         699,054         16,676,567   

 

     Shares For      Shares Against      Shares Abstaining      Broker Non-Votes  

Proposal 2

     25,369,902         289,394         89,484         —     


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    MELA Sciences, Inc.
Date: April 27, 2012     By:  

/s/ Richard Steinhart

      Name: Richard Steinhart
      Title: Chief Financial Officer